Policy

AbbVie Study Highlights Switching Costs for Rheumatic Biosimilars

May 20th 2021

By Tony Hagen

A study funded by AbbVie finds support for maintaining patients on originator rheumatic agents, such as Humira (adalimumab), rather than switching to biosimilars.

Quebec Makes It Harder to Use Originator Biologics

May 19th 2021

By Tony Hagen

Biosimilars were on formulary for years but nobody was using them, Canadian authorities explain as their reasons for dropping originators from approved lists.

AbbVie's Gonzalez Is on Defense as House Members Petition FTC

May 18th 2021

By Tony Hagen

Accused of unfair trade practices, AbbVie's CEO Richard Gonzalez pointed the finger at Medicare Part D.

Kaiser Permanente Investigators Confirm Mvasi Safety and Efficacy in Population With Nonsquamous NSCLC

May 18th 2021

The retrospective, real-world study (N = 353) conducted within the Kaiser Permanente network followed the July 2019 launch of the bevacizumab biosimilar Mvasi.

House Committee Issues Blistering Report on AbbVie's Humira Tactics

May 18th 2021

By Tony Hagen

The House Committee on Oversight and Reform contends AbbVie's "biosimilar defense strategy" has succeeded beyond the company's wildest imagination.

German Study Calculates Adalimumab Biosimilar Savings From Earlier Intervention

May 17th 2021

By Tony Hagen

Investigators evaluated both biosimilar vs originator savings and savings from earlier use of a lower-cost adalimumab biosimilar (Amgevita).

US, EU Regulators Discuss Tailoring Biosimilar Approvals

May 10th 2021

By Tony Hagen

During a talk at the Medicines for Europe Biosimilar Medicines Conference, US and EU regulators discuss the potential for tailored approach to bring biosimilars to market sooner with less expense and wasted effort.

Regulators Look Back on 15 Years of Biosimilars in Europe

May 7th 2021

By Tony Hagen

Advances in analytical testing have improved confidence in biosimilars, according to a Medicines for Europe panel.

The Difference Between an Interchangeable Biosimilar and One That Isn't

May 5th 2021

By Tony Hagen

The anatomy of an interchangeability switching study.

Amgen Canada Launches Adalimumab Biosimilar

May 4th 2021

Amgevita is now broadly available across Canada.